CClinicalTrials.gg
Not yet recruitingNCT07436403Updated Feb 27, 2026

Comparison of Post-Dural Puncture Headache After Spinal Anesthesia Using Median Versus Paramedian Approach

An interventional study of Spinal anesthesia using median approach (midline) and Spinal anesthesia using paramedian approach in Post-Dural Puncture Headache and Headache After Spinal Puncture, sponsored by Mayo Hospital Lahore. Not yet recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Mayo Hospital Lahore · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This randomized controlled trial will compare two commonly used techniques for performing spinal anesthesia, the median (midline) approach and the paramedian (lateral) approach, in adult patients undergoing elective orthopedic or urology surgery at Mayo Hospital, Lahore. Spinal anesthesia is widely used because it provides rapid pain control during surgery and avoids airway instrumentation. However, a recognized complication is post-dural puncture headache (PDPH), a headache that typically worsens on sitting or standing and improves on lying down. PDPH can delay mobilization, reduce oral intake, prolong hospital stay, and sometimes require additional treatment.

Eligible participants aged 18 to 65 years with American Society of Anesthesiologists (ASA) physical status I or II will be enrolled, and then allocated in a 1:1 ratio to receive spinal anesthesia using either the median or paramedian approach. To standardize the procedure, spinal anesthesia will be performed under aseptic technique at the L3 to L4 or L4 to L5 interspace using a 25-gauge Quincke spinal needle, followed by injection of a fixed dose of hyperbaric bupivacaine. Routine perioperative monitoring will be applied for all participants, and intra-operative blood pressure will be recorded at regular intervals to document hypotension.

The primary outcomes are the frequency and severity of PDPH. PDPH will be assessed using a structured checklist based on the International Classification of Headache Disorders, 3rd edition (ICHD-3) at 24 hours, 72 hours, and day 5 after the procedure by a trained assessor. Headache intensity will be recorded using a 0 to 10 Visual Analogue Scale, and categorized as mild, moderate, or severe. The hypothesis is that the frequency and severity of PDPH differ between the median and paramedian approaches in patients receiving spinal anesthesia for orthopedic or urology surgery.

02

Conditions studied

  • Post-Dural Puncture Headache
  • Headache After Spinal Puncture

Keywords

  • Post-dural puncture headache
  • Spinal anesthesia
  • Median approach
  • Paramedian approach
  • Randomized controlled trial
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Both gender (male and female) aged between 18 and 65.
  • Adults undergoing elective orthopedics or urology procedures planned under spinal anesthesia.
  • ASA status I or II.
  • Ability to give informed consent and comply with postoperative assessment.

Exclusion criteria

Exclusion Criteria:

  • Any contraindication to spinal anesthesia, including infection at puncture site, coagulopathy or therapeutic anticoagulation, thrombocytopenia, severe hypovolemia or shock, raised intracranial pressure due to space occupying lesion, or suspected spinal canal infection.
  • Known hypersensitivity to planned intrathecal local anesthetic or adjuvant drugs.
  • History of chronic daily headache, migraine requiring regular prophylaxis, or headache at baseline on the day of surgery.
  • Prior lumbar spine surgery, significant spinal deformity, or neurological disease affecting lower limb sensation that will interfere with neuraxial assessment.
  • Inability to complete follow-up assessments due to impaired cognition, severe psychiatric illness, or major communication barrier.
  • Emergency procedures.
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
142 participants (estimated)

Study arms

  • Experimental
    Group A (Median Approach)

    Participants will receive spinal anesthesia using the median (midline) approach for elective orthopedic or urology surgery. The spinal needle will be introduced in the midline through the interspinous space until free cerebrospinal fluid flow is obtained, followed by intrathecal injection of a fixed dose of hyperbaric bupivacaine.

    Procedure: Spinal anesthesia using median approach (midline)

  • Active comparator
    Group B (Paramedian Approach)

    Participants will receive spinal anesthesia using the paramedian approach for elective orthopedic or urology surgery. The needle entry point will be approximately 1 cm lateral and 1 cm caudal to the inferior border of the selected spinous process, directed medially and cephalad to access the subarachnoid space, followed by intrathecal injection of a fixed dose of hyperbaric bupivacaine.

    Procedure: Spinal anesthesia using paramedian approach

Interventions

  • ProcedureSpinal anesthesia using median approach (midline)

    Spinal anesthesia will be performed under aseptic technique at L3 to L4 or L4 to L5 using a 25-gauge Quincke spinal needle. After local infiltration with lignocaine 1% (2 mL), and confirmation of free cerebrospinal fluid flow, hyperbaric bupivacaine 0.75% (15 mg, 2 mL) will be injected intrathecally. Standard perioperative monitoring and postoperative care will be applied.

  • ProcedureSpinal anesthesia using paramedian approach

    Spinal anesthesia will be performed under aseptic technique at L3 to L4 or L4 to L5 using a 25-gauge Quincke spinal needle. After local infiltration with lignocaine 1% (2 mL), the needle will be inserted via the paramedian route (approximately 1 cm lateral and 1 cm caudal to the inferior border of the selected spinous process) and directed medially and cephalad. After confirmation of free cerebrospinal fluid flow, hyperbaric bupivacaine 0.75% (15 mg, 2 mL) will be injected intrathecally. Standard perioperative monitoring and postoperative care will be applied.

05

What researchers measure

Primary outcomes

  1. Incidence of post-dural puncture headache

    Proportion of participants developing post-dural puncture headache, defined as a headache occurring within 5 days after spinal anesthesia that worsens within 15 minutes of sitting or standing and improves within 15 minutes of lying down, with at least one associated feature (neck stiffness, tinnitus, hypoacusis, photophobia, or nausea). Diagnosis will be confirmed using a structured checklist based on International Headache Society International Classification of Headache Disorders, 3rd edition criteria.

    Time frame: 24 hours, 72 hours, and day 5 after spinal anesthesia

Secondary outcomes

  1. Severity of post-dural puncture headache

    Headache intensity measured using a 10 cm Visual Analogue Scale (0 to 10), recorded at each scheduled assessment. Severity will be categorized as mild (1 to 3), moderate (4 to 6), or severe (7 to 10).

    Time frame: 24 hours, 72 hours, and day 5 after spinal anesthesia

06

Study locations

1 site
  • Mayo Hospital, Lahore
    Lahore, Punjab Province 54000, Pakistan
07

Registry details

Key details

Study ID
NCT07436403
Lead sponsor
Mayo Hospital Lahore
Responsible party
Adeel Ahmed (Principal Investigator, Mayo Hospital Lahore) — Principal investigator
First posted
Feb 27, 2026
Start date
May 2026 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Feb 27, 2026

Study contacts

Ali Raza Ihsan Ihsan
Contact
aliraza45901@gmail.com
+923311491996
Ali Raza Ihsan
principal investigator · Mayo Hospital Lahore

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion